HARROW, INC.
Harrow, Inc. (Nasdaq: HARW) is a leading provider of ophthalmic disease management solutions in North America, operating through branded pharmaceutical products and a pharmaceutical compounding business. The company's website is www.harrow.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What HARROW, INC. does
In the company’s own words
Harrow, Inc. (Nasdaq: HARW) is a leading provider of ophthalmic disease management solutions in North America, operating through branded pharmaceutical products and a pharmaceutical compounding business. The company's website is www.harrow.com.
The company's core business comprises two primary segments: branded ophthalmic pharmaceuticals and ImprimisRx, an ophthalmology-focused pharmaceutical compounding operation. Harrow's branded portfolio includes over 20 FDA-approved ophthalmic products marketed and sold primarily in the United States and Canadian markets, addressing conditions affecting both the front and back of the eye, including dry eye disease, wet age-related macular degeneration, cataracts, glaucoma, and various ocular surface conditions. Key branded products include VEVYE for dry eye disease, IHEEZO for ocular surface anesthesia, TRIESENCE for ophthalmic disease treatment, and recently approved biosimilars BYOOVIZ and OPUVIZ. The company also markets established products such as VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, and VERKAZIA.
ImprimisRx operates two compounding facilities in Ledgewood, New Jersey, including a Section 503B FDA-registered outsourcing facility and a Section 503A licensed pharmacy. The compounding business serves more than 10,000 U.S. eyecare-dedicated prescribers and institutions with over 30 proprietary formulations, many of which are patented or patent-pending. All ImprimisRx finished products are manufactured in the United States.
Harrow's development pipeline focuses on late-stage and near-commercial assets, including MELT-300, a patented sublingual sedation therapy combining midazolam and ketamine for procedural use, which completed Phase 3 clinical trials. The company also develops H-N08, a triamcinolone acetonide program for inflammatory indications, and CR-01, a device-enabled conjunctival delivery system for ocular neoplasia.
The company operates as an accelerated filer with the SEC and maintains a disciplined, capital-efficient development strategy. Harrow's business model leverages its existing commercial infrastructure to promote and distribute products while pursuing strategic acquisitions and licensing arrangements to expand its ophthalmic portfolio across multiple disease states and therapeutic categories.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NASHVILLE, TN
- Fiscal year end
- December
- CIK
- 1360214
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns HARROW, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · HARROW, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
HARROW, INC.’s bonds, as funds hold them
Funds report holding 1 issues of HARROW, INC.’s debt, $98.79M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 8.63%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do HARROW, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of HARROW, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in HARROW, INC.'s last four quarterly filings that the numbers alone won't show?”